AN2 Therapeutics Inc

NASDAQ ANTX

Data sourced from

and

Download Data

AN2 Therapeutics Inc Cash Per Share 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -48.00%

AN2 Therapeutics Inc Cash Per Share 1 year YoY Change (%) is -48.00% for the Trailing 12 Months (TTM) ending March 31, 2024, a 45.46% change year over year. The cash per share represents the amount of cash available to each outstanding share of common stock. It is calculated by dividing the total cash by the weighted average number of shares outstanding. This metric provides insight into the cash position of the company on a per-share basis and can be used to evaluate the company's liquidity and ability to distribute cash to shareholders. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

AN2 Therapeutics Inc Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was 1.60, a -88.01% change year over year.
AN2 Therapeutics Inc Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was 13.31.

NASDAQ: ANTX

AN2 Therapeutics Inc

CEO	Mr. Joseph S. Zakrzewski
IPO Date	March 25, 2022
Location	United States
Headquarters	1800 El Camino Real, Menlo Park, CA, United States, 94027
Employees	41
Sector	Healthcare
Industry	Biotechnology

Description

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Key trends